Bas Jm Peters

Publications (2)3.97 Total impact

• Article: CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.

  Bas J M Peters, Ankie M Harmsze, Jurriën M ten Berg, Anke-Hilse Maitland-van der Zee, Mathieu M Tjoeng, Anthonius de Boer, Vera H M Deneer
  Pharmacogenomics 02/2011; 12(2):141-4. · 3.97 Impact Factor
• Source

  Available from: Anke-Hilse Maitland-van der Zee

  Article: Pharmacogenomic insights into treatment and management of statin-induced myopathy.

  Bas Jm Peters, Olaf H Klungel, Frank L Visseren, Anthonius de Boer, Anke-Hilse Maitland-van der Zee
  [show abstract] [hide abstract]
  ABSTRACT: Although statins are generally well tolerated, the most common adverse drug reaction from statin therapy is myopathy. This article reviews the current pharmacogenomic knowledge of statin-induced myopathy. Furthermore, we will discuss the importance of recent pharmacogenetic advances for the treatment and management of statin-induced myopathy. Variation in the SLCO1B1 gene is associated with increased incidence of statin-induced myopathy, particularly with simvastatin and less so with other statins. If different pharmacokinetic enzymes and transporters are responsible for susceptibility to myopathy, this may explain differences in the occurrence of statin-induced myopathy in individual patients. Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin for the lowest chance of developing myopathy.
  Genome Medicine 01/2009; 1(12):120.